Use of disease-modifying therapies for MS changed substantially during the pandemic among clinicians and patients, according to two studies presented at the European Academy of Neurology (EAN) 2022 annual meeting. Read More
Neurology
EAN 2022 HIGHLIGHTS – THURSDAY, JUNE 30 EDITION
June 30, 2022Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 29 Edition
June 28 Edition
NfL, GFAP elevated post-COVID
Long-term data for anti-CD20 agents
Improved cognitive processing speed with ofatumumab
Cognitive impairment may predict physical disability
B cell kinetics during pregnancy
Clinical tip of the day
Read More
EAN 2022 HIGHLIGHTS – WEDNESDAY, JUNE 29 EDITION
June 29, 2022Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 28 Edition
COVID vaccine response with ofatumumab
Delayed time to wheelchair with siponimod
HSCT – the Swiss experience
Vaccine response to BTK inhibitors
Clinical tip of the day
Read More
EAN 2022 HIGHLIGHTS – TUESDAY, JUNE 28 EDITION
June 28, 2022Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 29 Edition
Relapses uncommon after COVID vaccination
The aging MS patient
Ocrelizumab EID
Natalizumab EID
Clinical tip of the day
Read More
Revisions proposed for McDonald criteria
May 27, 2022A fourth revision of the McDonald diagnostic criteria is currently underway to address some of the conceptual and practical difficulties in the diagnosis of multiple sclerosis, according to Dr. Jeffrey Cohen, Cleveland Clinic, Cleveland, Ohio. His remarks were made at the 43rd International Neuroscience Symposium of the Université de Montréal, held May 3-5, 2022, in Montreal. Read More